X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/moleculin-announces-positive-interim-data-in-annamycin-mb-106-phase-1b2-aml-trial-302097561.html
https://www.indianpharmapost.com/news/venus-remedies-secures-marketing-approval-from-israel-colombia-for-two-oncology-drugs-15078
https://www.prnewswire.com/news-releases/moleculin-doses-first-subjects-in-phase-2-portion-of-clinical-trial-evaluating-annamycin-in-combination-with-cytarabine-ara-c-for-the-treatment-of-acute-myeloid-leukemia-aml-301943789.html
https://www.daiichisankyo.com/files/news/pressrelease/pdf/202307/20230720_E.pdf
https://www.fiercebiotech.com/biotech/nkarta-touts-cell-therapy-effectiveness-specific-lymphodepletion-regiment-durability
https://www.globenewswire.com/news-release/2023/06/05/2681819/0/en/Foghorn-Therapeutics-Announces-FDA-Has-Lifted-Clinical-Hold-on-Phase-1-Study-of-FHD-286-in-Relapsed-and-or-Refractory-AML-MDS-Patients.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-showcase-rapidly-expanding-oncology-pipeline-and-advances-in-current-product-portfolio-at-asco-2023-301809003.html
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-secures-eight-additional-provincial
https://www.clinicaltrialsarena.com/news/italy-moleculin-leukaemia-trial/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208485
https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-announces-72-mrd-negativity-rate-in-the-recently-completed-phase-1-study-of-actimab-a-in-combination-with-clag-m-for-patients-with-relapsed-or-refractory-aml-301444015.html
https://www.expresspharma.in/bdr-pharmaceuticals-launches-indias-first-generic-midostaurin-mstarin-to-treat-leukemia/
https://www.prnewswire.com/news-releases/bergenbio-presents-encouraging-updated-preliminary-data-from-phase-ii-study-in-relapsed-aml-patients-at-eha-virtual-meeting-301310754.html
https://www.prnewswire.com/news-releases/bergenbio-presents-encouraging-updated-preliminary-data-from-phase-ii-study-in-relapsed-aml-patients-at-eha-virtual-meeting-301310754.html
https://www.prnewswire.com/news-releases/oncopeptides-presents-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting-301289913.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients-301259059.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211938
https://www.businesswire.com/news/home/20191107005535/en/Ocuphire-Pharma-Announces-Results-Phase-2-Clinical/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://endpts.com/newsmakers-at-eha19-regeneron-arqule-track-progress-on-response-rates/
https://www.prnewswire.com/news-releases/biosight-receives-orphan-drug-designation-from-the-fda-for-bst-236-for-the-treatment-of-acute-myeloid-leukemia-300861446.html
https://www.oncnet.com/news/decitabine-plus-chemo-denotes-new-induction-therapy-option-aml-mds-features
https://seekingalpha.com/article/4224941-pfizer-receives-fda-approval-aml-drug?li_source=LI&li_medium=liftigniter-widget
http://www.pharmatimes.com/news/final_nice_green_light_for_pfizers_mylotarg_1260417
https://www.pharmaceutical-technology.com/news/company-news/nice-jazz-pharmaceuticals-vyxeos/
https://www.biospectrumasia.com/news/25/12036/-nice-recommends-vyxeos-for-specific-secondary-aml.html
https://www.ema.europa.eu/documents/overview/vyxeos-epar-medicine-overview_cs.pdf
http://www.prnewswire.co.uk/news-releases/vyxeos-receives-marketing-authorisation-in-the-european-union-for-treatment-of-certain-types-of-high-691777661.html
https://www.fiercepharma.com/marketing/waiting-green-light-jazz-staffs-up-for-excessive-sleep-treatment-and-vyxeos-push-europe
https://endpts.com/otsukas-886m-plus-drug-just-flopped-in-its-first-crucial-phiii-trial-for-frontline-aml/
https://www.prnewswire.com/news-releases/journal-of-clinical-oncology-publishes-pivotal-phase-3-data-for-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-849583154.html
http://www.pharmatimes.com/news/car-t_therapies_leap_towards_eu_approval_1242660
https://www.biospace.com/article/european-regulators-make-decisions-on-several-companies-drugs/
https://www.prnewswire.com/news-releases/national-comprehensive-cancer-network-adds-jazz-pharmaceuticals-vyxeos-daunorubicin-and-cytarabine-liposome-for-injection-to-clinical-practice-guidelines-in-oncology-300596110.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206190
http://www.pharmatimes.com/news/speedy_review_for_jazz_high-risk_aml_chemo_1210651
http://www.fiercepharma.com/regulatory/years-after-accelerated-approval-debacle-fda-panel-backs-pfizer-s-mylotarg
http://www.in-pharmatechnologist.com/Regulatory-Safety/Pacira-to-stop-making-DepoCyt-due-to-long-term-production-problems
http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-acceptance-of-nda-for-vyxeos-cpx-351-an-investigational-treatment-for-acute-myeloid-leukemia-with-priority-review-status-300466520.html
http://www.prnewswire.com/news-releases/diplomat-now-dispensing-rydapt-midostaurin-for-acute-myeloid-leukemia-300460388.html
https://www.pharmacompass.com/pdf/news/zhejiang-hisun-pharmaceutical-co-ltd-yantou-campus-fails-edqm-inspection-1483966941.pdf
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-presented-phase-3-trial-results-in-patients-with-high-risk-acute-myeloid-leukemia-demonstrating-vyxeos-cpx-351-significantly-improved-overall-survival-300279899.html
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-announces-positive-data-for-vyxeos-in-flt3-itd-mutated-acute-myeloid-leukemia-aml-cells-derived-from-patients-with-newly-diagnosed-aml-300252809.html
http://www.prnewswire.com/news-releases/celator-announces-phase-3-trial-for-vyxeos-cpx-351-in-patients-with-high-risk-acute-myeloid-leukemia-demonstrates-statistically-significant-improvement-in-overall-survival-300235620.html
http://www.prnewswire.com/news-releases/celator-pharmaceuticals-announces-participation-in-cardiff-university-clinical-trial-in-adults-with-acute-myeloid-leukemia-or-high-risk-myelodysplastic-syndrome-aml19-300202001.html
http://www.fiercepharmamanufacturing.com/story/mylan-expands-recalls-plants-spanked-fda-warning-letter/2015-08-20
http://www.biospectrumasia.com/biospectrum/news/221144/taigen-initiates-clinical-trial-leukemia-drug-china
Market Place
Share 
